title: The need for reflective consideration of an integrative understanding of cardiovascular consequences to PVP formulated C60 exposure.
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Wingard
authors.forename: Nathan A
authors.initials: NA
authors.lastname: Holland
authors.forename: Leslie C
authors.initials: LC
authors.lastname: Thompson
authors.forename: Jared M
authors.initials: JM
authors.lastname: Brown
authors.forename: Anita H
authors.initials: AH
authors.lastname: Lewin
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Sumner
authors.forename: Timothy R
authors.initials: TR
authors.lastname: Fennell
authors.forename: Achini K
authors.initials: AK
authors.lastname: Vidanapathirana
mesh_terms: D000818:Animals; D002264:Carboxylic Acids / Q000633:toxicity*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D002626:Chemistry, Pharmaceutical; D037741:Fullerenes / Q000633:toxicity*; D006801:Humans; D049329:Nanostructures; D010316:Particle Size; D018570:Risk Assessment; D012307:Risk Factors; D012995:Solubility
chemical_list: C416673:C60 carboxyfullerene; D002264:Carboxylic Acids; D037741:Fullerenes